Evidence map›Paper›PMID 31974826›Full record

ArticleCEN case reports2020

Plasma exchange combined with bortezomib-based chemotherapy is effective for early renal recovery in a patient with IgD-λ type multiple myeloma.

Hiroyuki Ueda, Hideaki Kuno, Daisuke Takahashi, Ai Katsuma, Ai Kimura, Akio Nakashima, Junichiro Kato, Mamiko Momoki, Rie Ohba, Nobuaki Dobashi and 4 more

Open access · bronzeAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in CEN case reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Hiroyuki UedaDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Nishi-shinbashi 3-25-8, Minato-ku, Tokyo, 105-8461, Japan. hi-ro@jikei.ac.jp.ORCID 0000-0002-3938-2208
Hideaki KunoDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Nishi-shinbashi 3-25-8, Minato-ku, Tokyo, 105-8461, Japan.
Daisuke TakahashiDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Nishi-shinbashi 3-25-8, Minato-ku, Tokyo, 105-8461, Japan.
Ai KatsumaDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Nishi-shinbashi 3-25-8, Minato-ku, Tokyo, 105-8461, Japan.
Ai KimuraDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Nishi-shinbashi 3-25-8, Minato-ku, Tokyo, 105-8461, Japan.
Akio NakashimaDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Nishi-shinbashi 3-25-8, Minato-ku, Tokyo, 105-8461, Japan.
Junichiro KatoDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Nishi-shinbashi 3-25-8, Minato-ku, Tokyo, 105-8461, Japan.
Mamiko MomokiDivision of Hematology and Oncology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Rie OhbaDivision of Hematology and Oncology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Nobuaki DobashiDivision of Hematology and Oncology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Izumi YamamotoDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Nishi-shinbashi 3-25-8, Minato-ku, Tokyo, 105-8461, Japan.
Tetsuya KawamuraDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Nishi-shinbashi 3-25-8, Minato-ku, Tokyo, 105-8461, Japan.
Yoichi MiyazakiDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Nishi-shinbashi 3-25-8, Minato-ku, Tokyo, 105-8461, Japan.
Takashi YokooDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Nishi-shinbashi 3-25-8, Minato-ku, Tokyo, 105-8461, Japan.
Jikei University School of Medicine · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The immunoglobulin (Ig) D type is a rare variant of multiple myeloma (MM), that accounts for 1-2% of all cases. Compared to the more common types of MM, IgD MM is known to have more severe symptoms at presentation, and a poorer prognosis. A woman was admitted to our hospital for severe acute kidney disease and disorder (AKD) and back pain, and was started on hemodialysis. The renal biopsy revealed light chain cast nephropathy. She was diagnosed with IgD-λ MM based on Bence-Jones protein expression and high IgD serum levels, and started bortezomib therapy with plasma exchange (PE). After three sessions of PE, the serum free light chain levels decreased by 92%, and she was withdrawn from dialysis. The patient underwent autologous transplantation and is still in remission, demonstrating the benefits of a bortezomib-based regimen in combination with PE for IgD MM with AKD.

Indexed as

Acute DiseaseAsian PeopleBence Jones ProteinBortezomibCombined Modality TherapyFemaleHumansImmunoglobulin DImmunoglobulin lambda-ChainsKidneyKidney DiseasesMiddle AgedMultiple MyelomaPlasma ExchangeProteasome InhibitorsRecovery of FunctionBence Jones ProteinBortezomibImmunoglobulin DImmunoglobulin lambda-ChainsProteasome InhibitorsAcute kidney disease and disorderIgD-Multiple myelomaPlasma exchangeRenal recovery

Identifiers

PMID31974826
PMCPMC7148401
OpenAlexW3001386044

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.